Capital & FinanceEvent: September 8, 2026
BrainChild Bio secured $116 million Series A financing.
Published
Signal category
Capital & Finance
Quote
“This Endpoints News story takes a closer look at our $116 million Series A financing”
— BrainChild Bio team
Company
BrainChild Bio
BrainChild Bio is harnessing the power of CAR-T cell technology for tumors in the central nervous system.
- Industry
- Biotechnology Research
- Company size
- 55 employees
We are a kids-first, clinical-stage biotechnology company focused on harnessing the power of CAR-T cell technology for tumors n the central nervous system (CNS), prioritizing pediatrics with plans to expand our technology to adult indications. We are building a platform to optimize the application of CAR-T technology in CNS tumors-- prioritizing diffuse intrinsic pontine glioma (DIPG) with plans to expand to other pediatric and adult brain tumors, including brain metastases.